γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells

Breast Cancer Research

Volumn 14, Issue 3, 2012, Pages

  Séveno, Céline ^a   Loussouarn, Delphine ^a,c   Bréchet, Sophie ^a   Campone, Mario ^a,b   Juin, Philippe ^a,b   Barillé Nion, Sophie ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b Institut de Cancé Rologie de L'Ouest ICO   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; BH3 PROTEIN; BIM PROTEIN; GAMMA SECRETASE INHIBITOR; GAMMA SECRETASE INHIBITOR 12; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN NOXA; PUMA PROTEIN; UNCLASSIFIED DRUG; ABT-737; BAX PROTEIN (53 86); BAX PROTEIN (53-86); BCL2L1 PROTEIN, HUMAN; BENZYLOXYCARBONYL ISOLEUCYL LEUCINAL; BENZYLOXYCARBONYL-ISOLEUCYL-LEUCINAL; BIPHENYL DERIVATIVE; DIPEPTIDE; MYELOID CELL LEUKEMIA SEQUENCE 1 PROTEIN; NITROPHENOL; NOTCH RECEPTOR; ONCOPROTEIN; PEPTIDE FRAGMENT; PIPERAZINE DERIVATIVE; PMAIP1 PROTEIN, HUMAN; PROTEIN BCL X; SECRETASE; SMALL INTERFERING RNA; SULFONAMIDE;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL DEATH; CONTROLLED STUDY; DOWNSTREAM PROCESSING; ENZYME INDUCTION; ENZYME INHIBITION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; PROTEIN TARGETING; SENSITIZATION; TUMOR MICROENVIRONMENT; UPREGULATION; BREAST TUMOR; CELL STRAIN MCF 7; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; METABOLISM; RNA INTERFERENCE; TUMOR CELL LINE;

AMYLOID PRECURSOR PROTEIN SECRETASES; APOPTOSIS; BCL-X PROTEIN; BIPHENYL COMPOUNDS; BREAST NEOPLASMS; CELL LINE, TUMOR; DIPEPTIDES; FEMALE; HUMANS; MCF-7 CELLS; NITROPHENOLS; PEPTIDE FRAGMENTS; PIPERAZINES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTORS, NOTCH; RNA INTERFERENCE; RNA, SMALL INTERFERING; SULFONAMIDES; TUMOR MICROENVIRONMENT;

EID: 84863208047     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3214     Document Type: Article

References (46)

1. Ranganathan P, Weaver KL, Capobianco AJ. Notch signalling in solid tumours: a little bit of everything but not all the time. Nature Rev Cancer 2011, 11:338-351.
2. Ellisen LW, Bird J, West DC, Soreng AL, Reynolds TC, Smith SD, Sklar J. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms. Cell 1991, 66:649-661. 10.1016/0092-8674(91)90111-B, 1831692.
3. Weng AP, Ferrando AA, Lee W, Morris JP, Silverman LB, Sanchez-Irizarry C, Blacklow SC, Look AT, Aster JC. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004, 306:269-271. 10.1126/science.1102160, 15472075.
4. Gallahan D, Jhappan C, Robinson G, Hennighausen L, Sharp R, Kordon E, Callahan R, Merlino G, Smith GH. Expression of a truncated Int3 gene in developing secretory mammary epithelium specifically retards lobular differentiation resulting in tumorigenesis. Cancer Res 1996, 56:1775-1785.
5. Reedijk M, Odorcic S, Chang L, Zhang H, Miller N, McCready DR, Lockwood G, Egan SE. High-level coexpression of JAG1 and NOTCH1 is observed in human breast cancer and is associated with poor overall survival. Cancer Res 2005, 65:8530-8537. 10.1158/0008-5472.CAN-05-1069, 16166334.
6. Pece S, Serresi M, Santolini E, Capra M, Hulleman E, Galimberti V, Zurrida S, Maisonneuve P, Viale G, Di Fiore PP. Loss of negative regulation by Numb over Notch is relevant to human breast carcinogenesis. J Cell Biol 2004, 167:215-221. 10.1083/jcb.200406140, 2172557, 15492044.
7. Rizzo P, Miao H, D'Souza G, Osipo C, Song LL, Yun J, Zhao H, Mascarenhas J, Wyatt D, Antico G, Hao L, Yao K, Rajan P, Hicks C, Siziopikou K, Selvaggi S, Bashir A, Bhandari D, Marchese A, Lendahl U, Qin JZ, Tonetti DA, Albain K, Nickoloff BJ, Miele L. Cross-talk between notch and the estrogen receptor in breast cancer suggests novel therapeutic approaches. Cancer Res 2008, 68:5226-5235. 10.1158/0008-5472.CAN-07-5744, 18593923.
8. Hao L, Rizzo P, Osipo C, Pannuti A, Wyatt D, Cheung LW, Sonenshein G, Osborne BA, Miele L. Notch-1 activates estrogen receptor-alpha-dependent transcription via IKKalpha in breast cancer cells. Oncogene 2010, 29:201-213. 10.1038/onc.2009.323, 19838210.
9. Osipo C, Patel P, Rizzo P, Clementz AG, Hao L, Golde TE, Miele L. ErbB-2 inhibition activates Notch-1 and sensitizes breast cancer cells to a gamma-secretase inhibitor. Oncogene 2008, 27:5019-5032. 10.1038/onc.2008.149, 18469855.
10. Dontu G, Jackson KW, McNicholas E, Kawamura MJ, Abdallah WM, Wicha MS. Role of Notch signaling in cell-fate determination of human mammary stem/progenitor cells. Breast Cancer Res 2004, 6:R605-R615. 10.1186/bcr920, 1064073, 15535842.
11. Tanos T, Brisken C. What signals operate in the mammary niche?. Breast Dis 2008, 29:69-82.
12. Kopan R, Ilagan MX. The canonical Notch signaling pathway: unfolding the activation mechanism. Cell 2009, 137:216-233. 10.1016/j.cell.2009.03.045, 2827930, 19379690.
13. Meurette O, Stylianou S, Rock R, Collu GM, Gilmore AP, Brennan K. Notch activation induces Akt signaling via an autocrine loop to prevent apoptosis in breast epithelial cells. Cancer Res 2009, 69:5015-5022.
14. Rasul S, Balasubramanian R, Filipović A, Slade MJ, Yagüe E, Coombes RC. Inhibition of gamma-secretase induces G2/M arrest and triggers apoptosis in breast cancer cells. Br J Cancer 2009, 100:1879-1888. 10.1038/sj.bjc.6605034, 2714234, 19513078.
15. Lee CW, Raskett CM, Prudovsky I, Altieri DC. Molecular dependence of estrogen receptor-negative breast cancer on a notch-survivin signaling axis. Cancer Res 2008, 68:5273-5281. 10.1158/0008-5472.CAN-07-6673, 2652573, 18593928.
16. Meng RD, Shelton CC, Li YM, Qin LX, Notterman D, Paty PB, Schwartz GK. gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity. Cancer Res 2009, 69:573-582. 10.1158/0008-5472.CAN-08-2088, 3242515, 19147571.
17. Stylianou S, Clarke RB, Brennan K. Aberrant activation of Notch signaling in human breast cancer. Cancer Res 2006, 66:1517-1525. 10.1158/0008-5472.CAN-05-3054, 16452208.
18. Harrison H, Farnie G, Brennan KR, Clarke RB. Breast cancer stem cells: something out of notching?. Cancer Res 2010, 70:8973-8976. 10.1158/0008-5472.CAN-10-1559, 21045140.
19. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000, 100:57-70. 10.1016/S0092-8674(00)81683-9, 10647931.
20. Du H, Wolf J, Schafer B, Moldoveanu T, Chipuk JE, Kuwana T. BH3 domains other than Bim and Bid can directly activate Bax/Bak. J Biol Chem 2011, 286:491-501. 10.1074/jbc.M110.167148, 3013008, 21041309.
21. Letai AG. Diagnosing and exploiting cancer's addiction to blocks in apoptosis. Nat Rev Cancer 2008, 8:121-132. 10.1038/nrc2297, 18202696.
22. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA, Bruncko M, Deckwerth TL, Dinges J, Hajduk PJ, Joseph MK, Kitada S, Korsmeyer SJ, Kunzer AR, Letai A, Li C, Mitten MJ, Nettesheim DG, Ng S, Nimmer PM, O'Connor JM, Oleksijew A, Petros AM, Reed JC, Shen W, Tahir SK, Thompson CB, Tomaselli KJ, Wang B, Wendt MD, et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681. 10.1038/nature03579, 15902208.
23. Campone M, Noël B, Grau M, Guillemin Y, Gautier F, Gouraud W, Charbonnel C, Campion L, Jézéquel P, Braun F, Barré B, Coqueret O, Barillé-Nion S, Juin P. c-Myc dependent expression of proapoptotic Bim renders HER2-overexpressing breast cancer cell dependent on antiapoptotic Mcl-1. Mol Cancer 2011, 10:110. 10.1186/1476-4598-10-110, 3175201, 21899728.
24. Ostasiewicz P, Zielinska DF, Mann M, Wiśniewski JR. Proteome, phosphoproteome, and N-glycoproteome are quantitatively preserved in formalin-fixed paraffin-embedded tissue and analyzable by high-resolution mass spectrometry. J Proteome Res 2010, 9:3688-3700. 10.1021/pr100234w, 20469934.
25. de Carné Trécesson S, Guillemin Y, Bélanger A, Bernard AC, Preisser L, Ravon E, Gamelin E, Juin P, Barré B, Coqueret O. Escape from p21-mediated oncogene-induced senescence leads to cell dedifferentiation and dependence on anti-apoptotic Bcl-xL and MCL1 proteins. J Biol Chem 2011, 286:12825-12838. 10.1074/jbc.M110.186437, 3075630, 21292770.
26. Hsieh JJ, Henkel T, Salmon P, Robey E, Peterson MG, Hayward SD. Truncated mammalian Notch1 activates CBF1/RBPJk-repressed genes by a mechanism resembling that of Epstein-Barr virus EBNA2. Mol Cell Biol 1996, 16:952-959. 231077, 8622698.
27. Yu X, Alder JK, Chun JH, Friedman AD, Heimfeld S, Cheng L, Civin CI. HES1 inhibits cycling of hematopoietic progenitor cells via DNA binding. Stem Cells 2006, 24:876-888. 10.1634/stemcells.2005-0598, 16513761.
28. Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, Blacklow SC, Kung AL, Gilliland DG, Verdine GL, Bradner JE. Direct inhibition of the NOTCH transcription factor complex. Nature 2009, 462:182-188. 10.1038/nature08543, 2951323, 19907488.
29. Han J, Ma I, Hendzel MJ, Allalunis-Turner J. The cytotoxicity of gamma-secretase inhibitor I to breast cancer cells is mediated by proteasome inhibition, not by gamma-secretase inhibition. Breast Cancer Res 2009, 11:R57. 10.1186/bcr2347, 2750119, 19660128.
30. Farnie G, Clarke RB, Spence K, Pinnock N, Brennan K, Anderson NG, Bundred NJ. Novel cell culture technique for primary ductal carcinoma in situ: role of Notch and epidermal growth factor receptor signaling pathways. J Natl Cancer Inst 2007, 99:616-627. 10.1093/jnci/djk133, 17440163.
31. Harrison H, Farnie G, Howell SJ, Rock RE, Stylianou S, Brennan KR, Bundred NJ, Clarke RB. Regulation of breast cancer stem cell activity by signaling through the Notch4 receptor. Cancer Res 2010, 70:709-718. 10.1158/0008-5472.CAN-09-1681, 20068161.
32. Qin JZ, Stennett L, Bacon P, Bodner B, Hendrix MJ, Seftor RE, Seftor EA, Margaryan NV, Pollock PM, Curtis A, Trent JM, Bennett F, Miele L, Nickoloff BJ. p53-independent NOXA induction overcomes apoptotic resistance of malignant melanomas. Mol Cancer Ther 2004, 8:895-902.
33. Ploner C, Kofler R, Villunger A. Noxa: at the tip of the balance between life and death. Oncogene 2008, 27(Suppl 1):S84-S92. 3272398, 19641509.
34. Czabotar PE, Lee EF, van Delft MF, Day CL, Smith BJ, Huang DC, Fairlie WD, Hinds MG, Colman PM. Structural insights into the degradation of Mcl-1 induced by BH3 domains. Proc Natl Acad Sci USA 2007, 104:6217-6222. 10.1073/pnas.0701297104, 1851040, 17389404.
35. Konopleva M, Contractor R, Tsao T, Samudio I, Ruvolo PP, Kitada S, Deng X, Zhai D, Shi YX, Sneed T, Verhaegen M, Soengas M, Ruvolo VR, McQueen T, Schober WD, Watt JC, Jiffar T, Ling X, Marini FC, Harris D, Dietrich M, Estrov Z, McCubrey J, May WS, Reed JC, Andreeff M. Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia. Cancer Cell 2006, 10:375-388. 10.1016/j.ccr.2006.10.006, 17097560.
36. Oakes SR, Vaillant F, Lim E, Lee L, Breslin K, Feleppa F, Deb S, Ritchie ME, Takano E, Ward T, Fox SB, Generali D, Smyth GK, Strasser A, Huang DC, Visvader JE, Lindeman GJ. Sensitization of BCL-2-expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737. Proc Natl Acad Sci USA 2012, 109:2766-2771. 10.1073/pnas.1104778108, 21768359.
37. Albershardt TC, Salerni BL, Soderquist RS, Bates DJ, Pletnev AA, Kisselev AF, Eastman A. Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA. J Biol Chem 2011, 286:24882-24895. 10.1074/jbc.M111.255828, 21628457.
38. Bray K, Chen HY, Karp CM, May M, Ganesan S, Karantza-Wadsworth V, DiPaola RS, White E. Bcl-2 modulation to activate apoptosis in prostate cancer. Mol Cancer Res 2009, 7:1487-1496. 10.1158/1541-7786.MCR-09-0166, 2855683, 19737977.
39. Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA, Lander ES. Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell 2009, 138:645-659. 10.1016/j.cell.2009.06.034, 19682730.
40. Grudzien P, Lo S, Albain KS, Robinson P, Rajan P, Strack PR, Golde TE, Miele L, Foreman KE. Inhibition of Notch signaling reduces the stem-like population of breast cancer cells and prevents mammosphere formation. Anticancer Res 2010, 30:3853-3867.
41. Lang JY, Hsu JL, Meric-Bernstam F, Chang CJ, Wang Q, Bao Y, Yamaguchi H, Xie X, Woodward WA, Yu D, Hortobagyi GN, Hung MC. BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell 2011, 20:341-356. 10.1016/j.ccr.2011.07.017, 21907925.
42. Houde C, Li Y, Song L, Barton K, Zhang Q, Godwin J, Nand S, Toor A, Alkan S, Smadja NV, Avet-Loiseau H, Lima CS, Miele L, Coignet LJ. Overexpression of the NOTCH ligand JAG2 in malignant plasma cells from multiple myeloma patients and cell lines. Blood 2004, 104:3697-3704. 10.1182/blood-2003-12-4114, 15292061.
43. Zeng Q, Li S, Chepeha DB, Giordano TJ, Li J, Zhang H, Polverini PJ, Nor J, Kitajewski J, Wang CY. Crosstalk between tumor and endothelial cells promotes tumor angiogenesis by MAPK activation of Notch signaling. Cancer Cell 2005, 8:13-23. 10.1016/j.ccr.2005.06.004, 16023595.
44. van der Kuip H, Mürdter TE, Sonnenberg M, McClellan M, Gutzeit S, Gerteis A, Simon W, Fritz P, Aulitzky WE. Short term culture of breast cancer tissues to study the activity of the anticancer drug taxol in an intact tumor environment. BMC Cancer 2006, 6:86-97. 10.1186/1471-2407-6-86, 1456977, 16603054.
45. Cullion K, Draheim KM, Hermance N, Tammam J, Sharma VM, Ware C, Nikov G, Krishnamoorthy V, Majumder PK, Kelliher MA. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model. Blood 2009, 113:6172-6181. 10.1182/blood-2008-02-136762, 2699237, 19246562.
46. van Es JH, van Gijn ME, Riccio O, van den Born M, Vooijs M, Begthel H, Cozijnsen M, Robine S, Winton DJ, Radtke F, Clevers H. Notch/gamma-secretase inhibition turns proliferative cells in intestinal crypts and adenomas into goblet cells. Nature 2005, 435:959-963. 10.1038/nature03659, 15959515.